ABSTRACT
Preservation of photoreceptors beyond areas of retinal pigment epithelium atrophy is a critical treatment goal in eyes with geographic atrophy (GA) to prevent vision loss. Thus, we assessed the association of treatment with the complement C3 inhibitor pegcetacoplan with optical coherence tomography (OCT)-based photoreceptor laminae thicknesses in this post hoc analysis of the FILLY trial (NCT02503332).
Retinal layers in OCT were segmented using a deep-learning-based pipeline and extracted along evenly spaced contour-lines surrounding areas of GA. The primary outcome measure was change from baseline in (standardized) outer nuclear layer (ONL) thickness at the 5.16°-contour-line at month 12.
Participants treated with pegcetacoplan monthly had a thicker ONL along the 5.16° contour-line compared to the pooled sham arm (mean difference [95% CI] +0.29 z-score units [0.16, 0.42],P<.001). The same was evident for eyes treated with pegcetacoplan every other month (+0.26 z-score units [0.13, 0.4],P<.001). Additionally, eyes treated with pegcetacoplan exhibited a thicker photoreceptor inner segment layer along the 5.16°-contour-line at month 12.
These findings suggest that pegcetacoplan could slow GA progression and lead to a lesser thinning of photoreceptor layers beyond the GA boundary. Future trials in earlier disease stages, i.e., intermediate AMD, aiming to slow photoreceptor degeneration warrant consideration.
Competing Interest Statement
Competing interests Funding: This study was funded by Apellis Pharmaceuticals, Waltham, Massachusetts, USA. Methods development relevant to this work was supported by a National Institutes of Health Core Grant (EY014800), and an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology … Visual Sciences, University of Utah, and the German Research Foundation (DFG) grant no.: PF950/1-1 (to MP), and FL658/4-1 and FL658/4-2 (to MF). Financial Disclosures: M. Pfau reports personal fees from Apellis and Novartis outside the submitted work. S. Schmitz-Valckenberg reports grants from Acucela/Kubota Vision, personal fees from Apellis, grants and personal fees from Novartis, grants and personal fees from Allergan, grants and personal fees from Bayer, grants and personal fees from Bioeq/Formycon, grants, personal fees and non-financial support from Carl Zeiss MediTec AG, grants and non-financial support from Centervue, personal fees from Galimedix, grants, personal fees and non-financial support from Heidelberg Engineering, grants from Katairo, non-financial support from Optos, personal fees from Oxurion, outside the submitted work. Ramiro Ribeiro is employed by Apellis Pharmaceuticals, Waltham, Massachusetts, USA. Reza Safaei is employed by Apellis Pharmaceuticals, Waltham, Massachusetts, USA. Alex McKeown is employed by Apellis Pharmaceuticals, Waltham, Massachusetts, USA. M. Fleckenstein reports grants, personal fees and non-financial support from Heidelberg Engineering, non-financial support from Zeiss Meditech, grants and non-financial support from Optos, personal fees and grant from Novartis, personal fees from Bayer, grants and personal fees from Genentech, from Roche, outside the submitted work; In addition, Dr. Fleckenstein is an inventor on a patent US20140303013 A1 pending. F.G. Holz reports personal fees from Acucela, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, Roche/Genentech, Geuder, Graybug, Gyroscope, Heidelberg Engineering, IvericBio, Kanghong, LinBioscience, Novartis, Oxurion, Pixium Vision, Oxurion, Stealth BioTherapeutics, and Zeiss. Prof. Holz reports grants from Allergan, Apellis, Bayer, Bioeq/Formycon, CenterVue, Ellex, Roche/Genentech, Geuder, Heidelberg Engineering, IvericBio, Kanghong, NightStarX, Novartis, Optos, Pixium Vision, and Zeiss. Role of Sponsor: The sponsor or funding organizations had no role in the conduct of the analysis but were involved in the interpretation of the data, preparation, review, and approval of the manuscript. The authors alone are responsible for the content and writing of the paper. The views expressed are those of the authors.
Clinical Trial
NCT02503332
Funding Statement
Funding: This study was funded by Apellis Pharmaceuticals, Waltham, Massachusetts, USA. Methods development relevant to this work was supported by a National Institutes of Health Core Grant (EY014800), and an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology … Visual Sciences, University of Utah, and the German Research Foundation (DFG) grant no.: PF950/1-1 (to MP), and FL658/4-1 and FL658/4-2 (to MF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The New England Institutional Review Board, University of Miami, Mayo Clinic, Institutional Review Board of the Cleveland Clinic Foundation, Duke University Health System Institutional Review Board, and Research Compliance Office, Stanford University (all U.S.A), Bellberry Ltd (Australia), and the Northern A Health and Disability Ethics Committee, Health and Disability Ethics Committees, and Ministry of Health (New Zealand) gave ethical approval for this work. See also: Liao, D. S. et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology 127, 186 (2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.